Clinical research of fentanyl patch

An observational, case-control study to explore the influencing factors of end of dose failure (EDF) in the use of fentanyl patch in Chinese patients with cancer pain

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100042423

Enrollment

Unknown

Registered

2021-01-21

Start date

2021-01-07

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer pain

Interventions

Pain relief time less than 72 hours group vs. pain relief time lasted for 72 hours group:Nil

Eligibility

Sex/Gender

All

Age

No minimum to 100 Years

Inclusion criteria

Inclusion criteria: 1. The diagnosis evidence of malignant tumor; 2. Moderate and severe cancer pain; 3. The use of fentanyl transdermal patch; 4. The patch in the skin fitting <= 72h ; 5. Clear consciousness; 6. Can express the use dose and duration of the patch; 7. Accept pharmacist following-up and consultation.

Exclusion criteria

Exclusion criteria: The patch was torn off in advance due to adverse reactions or poor adhesion.

Design outcomes

Primary

Measure	Time frame
duration;	—

Countries

China

Contacts

Public ContactRen Xiayang

Cancer Hospital, Chinese Academy of Medical Sciences

erxia100@163.com+86 15010377247

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026